What total cholesterol and LDL‑lowering agents are available besides statins and ezetimibe (Zetia)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

LDL and Total Cholesterol-Lowering Agents Beyond Statins and Ezetimibe

The primary alternatives to statins and ezetimibe are PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), bempedoic acid, and bile acid sequestrants, with PCSK9 monoclonal antibodies being the most effective and best-validated option for cardiovascular outcomes. 1

First-Line Add-On: PCSK9 Inhibitors

PCSK9 monoclonal antibodies (evolocumab and alirocumab) should be your first choice when additional LDL-lowering beyond statins and ezetimibe is needed. These agents reduce LDL-C by 50-60% and have proven cardiovascular outcomes benefits in the FOURIER and ODYSSEY Outcomes trials 1. They work by binding to PCSK9 protein, increasing the number of LDL receptors available to clear cholesterol from the blood 1.

When to Use PCSK9 Inhibitors:

  • Patients requiring >25% additional LDL-C reduction beyond maximally tolerated statin therapy
  • Very high-risk patients with ASCVD who haven't reached LDL-C <70 mg/dL despite statin + ezetimibe
  • Patients with baseline LDL-C ≥190 mg/dL not at goal on combination therapy 1

Inclisiran is a newer PCSK9 inhibitor using siRNA technology that requires only twice-yearly dosing after initial loading, offering a significant adherence advantage 2. However, cardiovascular outcomes data are still maturing (ORION-4 and VICTORION-2P trials ongoing) 1.

Second-Line Oral Option: Bempedoic Acid

Bempedoic acid provides approximately 17% additional LDL-C reduction and is particularly valuable in statin-intolerant patients. 1 It works through liver-selective inhibition of ATP-citrate lyase, upstream of the statin pathway 2. The CLEAR Outcomes trial demonstrated cardiovascular event reduction in statin-intolerant populations 3, 2.

Key Advantages:

  • Oral administration (preferred by injection-averse patients)
  • Does NOT cause muscle symptoms like statins 3
  • Can be combined with statins, ezetimibe, or both 1

Important Caveats:

  • Use with caution in patients with gout history - increases uric acid levels slightly 1, 3
  • Avoid in patients with tendon rupture history 1

Specialized Agents for Specific Phenotypes

For Severe Hypertriglyceridemia:

  • Icosapent ethyl (high-dose EPA): The REDUCE-IT trial showed significant cardiovascular event reduction in statin-treated patients with persistent triglycerides ≥150 mg/dL 2
  • ApoC-III inhibitors (olezarsen, plozasiran): Drive large triglyceride reductions, particularly useful in severe hypertriglyceridemia and pancreatitis-prone syndromes 2

For Refractory Familial Hypercholesterolemia:

  • Evinacumab (ANGPTL3 inhibitor): Works through LDL receptor-independent mechanisms, expanding options for homozygous familial hypercholesterolemia 2

Bile Acid Sequestrants:

These older agents (cholestyramine, colesevelam) reduce LDL-C by 15-30% but have significant gastrointestinal side effects and drug interactions 1. They are rarely first-choice today given better-tolerated alternatives, but may be considered in specific situations like pregnancy or young patients where long-term safety data are paramount.

Practical Sequencing Algorithm

For patients not at goal on maximally tolerated statin:

  1. Add ezetimibe first (you've already done this per your question)

  2. If still not at goal after statin + ezetimibe:

    • Need >25% additional reduction OR very high risk → PCSK9 mAb (evolocumab/alirocumab)
    • Need <25% additional reduction OR cost/injection concerns → Bempedoic acid
    • Statin-intolerant → Bempedoic acid preferred 1

  3. If still not at goal on triple therapy:

    • Consider simultaneous addition of both bempedoic acid AND PCSK9 inhibitor in very high-risk patients 1
    • Refer to lipid specialist 1

Critical Implementation Barriers

Cost and prior authorization remain the primary obstacles to using these agents. 2 PCSK9 inhibitors and newer therapies face significant insurance barriers, and uninsured patients may encounter prohibitive out-of-pocket costs without manufacturer assistance programs 2. Injection logistics and patient reluctance to injectable therapy have limited PCSK9 inhibitor uptake despite proven efficacy 4, 2.

Emerging Options

Obicetrapib (next-generation CETP inhibitor) is an oral agent in late-stage development showing substantial lipid effects, with outcomes trials in progress 4, 2. This may provide another oral alternative if approved.

References

2
Research

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Journal of clinical medicine research, 2026

Related Questions

What are the treatment guidelines for an 80-year-old woman with elevated low-density lipoprotein cholesterol who has no severe liver disease, statin intolerance, or active heart failure?
What are alternative therapies to statins for lowering LDL cholesterol in patients who cannot tolerate statins?
What are appropriate alternative statins or non‑statin lipid‑lowering agents for a patient who cannot use rosuvastatin?
What alternative lipid‑lowering therapy can be used for a patient allergic to evolocumab (Repatha) who cannot take any statin?
In a 69-year-old man whose LDL cholesterol remains 4 mmol/L while taking a statin and evolocumab (Repatha), what should be the next management steps?
What is the most likely diagnosis in a patient with purulent ocular discharge, polydipsia, agitation, and fever?
Are military avionics electronics technicians at increased risk for lumbar degenerative disc disease?
In a 64‑year‑old man with a one‑week history of dizziness, mild hyponatremia, impaired renal function, elevated B‑type natriuretic peptide, and modestly elevated high‑sensitivity troponin, who has already undergone basic metabolic panel, complete blood count, liver enzymes, cardiac biomarkers, BNP, vitamin B12, thyroid‑stimulating hormone, CT head, MRI brain, CTA head and neck, and chest X‑ray, what additional diagnostic tests should be ordered?
In an elderly female with multiple drug allergies who has a urinary tract infection caused by Escherichia coli susceptible to nitrofurantoin but develops a rash to nitrofurantoin (Macrobid), what intravenous antibiotic regimen should be used?
What non‑stimulant medication should be trialed next for a 17‑year‑old female with inattentive attention‑deficit/hyperactivity disorder (ADHD) and suspected personality disorder who has not responded to methylphenidate (Ritalin), dexmethylphenidate (Focalin), and extended‑release methylphenidate (Concerta), and who experienced limited benefit but marked appetite suppression with amphetamine/dextroamphetamine (Adderall)?
What is the significance of a nondiagnostic MR elastography that cannot assess hepatic fibrosis but shows hepatic iron deposition with lobar redistribution in a patient with elevated ferritin who consumes alcohol?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.